Last $1.20 USD
Change Today +0.02 / 1.69%
Volume 2.9K
BOPH On Other Exchanges
Symbol
Exchange
Stuttgart
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

bohai pharmaceuticals group (BOPH) Snapshot

Open
$1.20
Previous Close
$1.18
Day High
$1.20
Day Low
$1.20
52 Week High
05/27/14 - $2.06
52 Week Low
12/11/13 - $0.20
Market Cap
21.4M
Average Volume 10 Days
20.2K
EPS TTM
$1.01
Shares Outstanding
17.9M
EX-Date
--
P/E TM
1.2x
Dividend
--
Dividend Yield
--
Current Stock Chart for BOHAI PHARMACEUTICALS GROUP (BOPH)

Related News

No related news articles were found.

bohai pharmaceuticals group (BOPH) Related Businessweek News

No Related Businessweek News Found

bohai pharmaceuticals group (BOPH) Details

Bohai Pharmaceuticals Group, Inc., through its subsidiaries, produces, manufactures, and distributes herbal pharmaceuticals based on traditional Chinese medicine in the People’s Republic of China. The company offers seven varieties of approved traditional Chinese herbal medicines comprising four prescription drugs and three over the counter products in six delivery systems, including tablets, granules, capsules, formulations, concentrated powder, and medicinal wine for addressing rheumatoid arthritis, viral infections, gynecological diseases, cardio vascular issues, and respiratory diseases. Its products include Lung Nourishing syrup to moisten the lung and relieve coughs; Tongbi capsules to promote blood circulation and relieve swelling and pain; Tongbi tablets to regulate and fortify the blood promote blood circulation and relieve swelling pain; Zhuangyuan Shenhailong medicinal wine to promote kidney function; and BazhenYimu cream for menstruation conditioning. The company’s products also comprise Fangfengtongsheng granules to treat fever, headache, constipation, measles, and eczema; Zhengxintai capsules to improve kidney function and treat coronary artery disease and angina. It sells its products through hospitals, local pharmacies, and retail drug store chains. The company is headquartered in Yantai, China.

827 Employees
Last Reported Date: 07/16/14

bohai pharmaceuticals group (BOPH) Top Compensated Officers

Founder, Chairman, Chief Executive Officer, P...
Total Annual Compensation: $69.3K
Compensation as of Fiscal Year 2013.

bohai pharmaceuticals group (BOPH) Key Developments

Bohai Pharmaceuticals Group, Inc. Announces Change of Auditors

Effective September 15, 2014, Bohai Pharmaceuticals Group, Inc. dismissed its independent registered public accounting firm, Marcum Bernstein & Pinchuk LLP (Marcum) effective immediately. The dismissal was approved by the Board of Directors of the company. Effective September 15, 2014, the company engaged Parker Randall CF (H.K.) CPA Limited (Parker) as the company's independent registered public accountant.

Bohai Pharmaceuticals Group, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended March 31, 2014

Bohai Pharmaceuticals Group, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended March 31, 2014. For the quarter, the company reported net revenues of $39,722,126 against $34,786,624 a year ago. Income from operations was $5,770,780 against $4,650,363 a year ago. Income before provision for income taxes was $5,437,402 against $4,196,087 a year ago. Net income was $3,928,011 or $0.19 per diluted share against $3,159,206 or $0.15 per diluted share a year ago. The increase in Bohai's third fiscal quarter net revenues compared to the same period a year ago was primarily due to an 11% increase in revenues contributed by the company's three leading TCM products: Lung Nourishing Syrup, and Tongbi Capsules and Tongbi Tablets for treatment of arthritis, which together accounted for over 96% of the company's net revenues in both the current fiscal year quarter and first nine-month period. The increase in the company's net income was attributable mostly to an increase in total gross profit of $3,729,763, offset by an increase in operating expenses of $2,609,346 for this year compared to the same period a year ago. For the nine months period, the company reported net revenues of $129,284,445 against $111,067,950 a year ago. Income from operations was $25,902,589 against $19,962,821 a year ago. Income before provision for income taxes was $24,393,703 against $19,790,160 a year ago. Net income was $18,024,773 or $0.85 per diluted share against $14,813,455 or $0.71 per diluted share a year ago. Bohai's improvement in fiscal 2014 nine month net Revenue was due primarily to a net increase in revenues of 18% from the above three products. The increase in the company's net income during the first nine months of fiscal 2014 compared to the same period a year ago was attributable mostly to an increase in total gross profit of $14,435,545, offset by an increase in operating expenses of $8,495,777.

Bohai Pharmaceuticals Group, Inc. Provides Preliminary Financial Guidance for the Third Quarter Ended March 31, 2014

Bohai Pharmaceuticals Group, Inc. provided preliminary financial guidance for the third quarter ended March 31, 2014. The company's estimated total revenue and net income for the third quarter of 2014 are proximately $35 million and $3.4 million as compared to $34.8 million and $3.2 million for the same period for the fiscal year 2013. The company currently produces seven traditional Chinese medicine products in China, among which two are on the State Essential Drugs List (the EDL), one is on the Provincial Essential Drugs list, five are on the National Drugs Reimbursement List, five have the Exclusive Drugs status, and two have the State Protected Chinese Medicine Status.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BOPH:US $1.20 USD +0.02

BOPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BOPH.
View Industry Companies
 

Industry Analysis

BOPH

Industry Average

Valuation BOPH Industry Range
Price/Earnings 1.2x
Price/Sales 0.1x
Price/Book 0.2x
Price/Cash Flow 0.9x
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BOHAI PHARMACEUTICALS GROUP, please visit www.bohaipharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.